HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Preventive effect of dipropylacetamide in bipolar manic-depressive psychoses].

Abstract
Dipropylacetamide (DEPAMIDE) was administered to 60 patients with bipolar manic-depressive psychoses. The dosage was 900 mg per day, administered orally. In 5 (8%) of the patients gastrointestinal disorders were observed. Administration of lithium carbonate results in undesirable side-effects in 50% of the cases. Our clinical experience shows dipropylacetamide to have a considerably slighter toxic effect on the human organism than lithium carbonate. We regard Dipropylacetamide (DEPAMIDE) as a valuable and significant addition in the prophylaxis of affective disorders, notably bipolar manic-depressive psychoses.
AuthorsE Vencovský, E Peterová, J Kabes
JournalPsychiatrie, Neurologie, und medizinische Psychologie (Psychiatr Neurol Med Psychol (Leipz)) Vol. 39 Issue 6 Pg. 362-4 (Jun 1987) ISSN: 0033-2739 [Print] Germany
Vernacular TitleDie prophylaktische Wirkung von Dipropylazetamid bei bipolaren manisch-depressiven Psychosen.
PMID3116572 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Anticonvulsants
  • Valproic Acid
  • dipropylacetamide
Topics
  • Anticonvulsants (therapeutic use)
  • Bipolar Disorder (prevention & control)
  • Humans
  • Valproic Acid (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: